R&D The secrets of the secretome, with Hans Keirstead Immunis CEO Hans Keirstead explains why his company thinks the immune system is key to tackling healthspan and longevity.
R&D Changing Faces: Board appointments, November and December 20... As 2025 came to a close, we also saw a modest number of Board appointments, on both advisory and governance Boards.
R&D Saudi pharma’s rise as a global CDMO destination: Investment... Saudi Arabia is steadily establishing itself as a competitive worldwide destination for contract development and manufacturing.
R&D The frontier of 3D biofabrication in the race for healthy lo... pharmaphorum in conversation with Immortal Dragons and Frontier Bio about 3D tissue biofabrication and the race for healthy longevity.
R&D More than manufacturing: The value of a patient-centric CDMO For a biopharmaceutical company, contracting a CDMO that considers itself accountable to the patients can deliver a tangibly different experience.
R&D Changing Faces: Pharma and biotech hires, November and Decem... In our final batch of Changing Faces columns from 2025, we’re detailing a flurry of senior leadership appointments in recent months.
News EMA seeks input on virtual alternative to animal test EMA delivers a milestone in the replacement of animals in drug testing with the qualification of a virtual model for repeat-dose toxicity studies.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
